Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors

British Journal of Dermatology

Volumn 141, Issue 5, 1999, Pages 802-810

  Powell, T J ^a   Ben Bassat, H ^b   Klein, B Y ^b   Chen, H ^a   Shenoy, N ^a   McCollough, J ^c   Narog, B ^a   Gazit, A ^d   Harzstark, Z ^b   Chaouat, M ^b   Levitzki, R ^b   Tang, C ^a   McMahon, J ^a   Shawver, L ^a   Levitzki, A ^d  

^a SUGEN INC   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Epidermal growth factor receptor; Keratinocytes; Psoriasis; Quinazolines; Tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3' BROMOPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; ANTIPSORIASIS AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; DNA REPLICATION; DRUG POTENCY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIDERMIS; HUMANS; KERATINOCYTES; MICE; PSORIASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN ABSORPTION; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0032737020     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.03152.x     Document Type: Article

References (33)

1. 1 Gottlieb AB, Krueger JG. Growth factors, cytokines, and eicosanoids in psoriasis pathogenesis. In: Psoriasis (Dubertret L, ed.). Brescia, Italy: ISED Publishing, 1994: 18-28.
2. 2 Krueger JG. Krane JG, Carter DM et al. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990; 94: 135-40S.
3. 3 Brown KD. The EGF/transforming growth factor alpha family and their factors. Eur J Gastroenterol Hepatol 1995: 7: 914-22.
4. 4 Fantl WJ, Johnson DE, Williams LT, Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993; 62: 453-81.
5. 5 Gottlieb AB, Chang CK, Posnett DN et al. Detection of transforming growth factor-α in normal, malignant, and hyperproliferative human keratinocytes, J Kxp Med 1988; 167: 670-5.
6. 6 Coffey RJ, Derynck R, Wilcox JN et al. Production and auto-induction of transforming growth factor α in human keratinocytes. Nature 1987; 328: 817-20.
7. 7 Elder JT, Fisher GJ, Lindquist PB et al. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989: 243: 811-14.
8. 8 Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation. Genes Dev 1991: 5: 714-27.
9. 9 Finzi E, Harkins R, Horn T, TGF-α is widely expressed in differentiated as well as hyperproliferative skin epithelium. J Invest Dermatol 1991: 96: 328-32.
10. 10 King LE, Gates RE, Stoscheck CM et al. The EGF/TGF-α receptor in skin. J Invest Dermatol 1990; 94: 164-70S.
11. 11 Nanney LB, Stoscheck CM, Magid M et al. Altered epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1985; 86: 260-5.
12. 12 Nanney LB, Stoscheck CM, King LE. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83: 385-93.
13. 13 Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985; 85: 239-45.
14. 14 Ellis DL, Kafka SP, Chow JC er al. Melanoma growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons. N Engl J Med 1987; 317: 1582-7.
15. 15 Valyi-Nagy I, Jensen PJ, Albelda SM et al. Cytokine-induced expression of transforming growth factor α and the epidermal growth factor receptor in neonatal skin expiants. J Invest Dermatol 1992; 99: 350-6.
16. 16 Dvir A, Milner Y, Chomsky O et al. The inhibition of EGF dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J Cell Biol 1991; 113: 857-65.
17. 17 Ben-Bassat H, Vardi DY, Gasit A et al. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol 1995; 4: 82-8.
18. 18 Gazit A, Chen J. App H et al. Tyrphostins IV-highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 1996; 8: 1203-7.
19. 19 Ward WHJ, Cook PN, Slater AM et al. Epidermal growth factor receptor tyrosine kinase investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48: 639-46.
20. 20 Fry DW, Karaker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994; 265: 1093.
21. 21 Osherov N, Levitzki A. Epidermal growth factor dependent activation of Src family kinases. Eur J Biochem 1994; 225: 1047-53.
22. 22 Shawver LK, Schwartz DP, Mann E et al. Inhibition of PDGF mediated signal transduction and tumor growth by N-(4-trifluoromethyl) phenyl 5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167-77.
23. 23 Lipson KE, Pang L, Huber LJ et al. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 1998; 285: 844-52.
24. 24 Rheinwald JG, Green H. EGF and the multiplication of cultured human epidermal keratinocytes. Nature 1977: 265: 421-4.
25. 25 Kumar S, Behl CR, Pate SB et al. A simple microwave technique for the separation of epidermis and dermis in skin uptake studies. Pharmaceut Res 1989; 6: 740-1.
26. 26 Bronaugh RL. Preparation of biological membranes. In: Methods for Skin Absorption (Kempanien B, Reifenrath WG, eds). Boca Raton: CRC Press, 1990: 61-6.
27. 27 Kemey L, Michael G, Doboz A et al. Cytokine system as a potential target for antipsoriatic therapy. Exp Dermatol 1994; 3: 1-8.
28. 28 van de Kerkhof PC. Common pathways for epidermal growth and inflammation and their relevance in the patlhogenesis of psoriasis. Int J Dermatol 1991; 30: 755-62.
29. 29 McKay IA, Leigh IM. Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol 1995: 13: 105-14.
30. 30 Joffes EW. McCullough JL, Pittelkow MR et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxiz and growth-inhibition effects of methotrexate. J Invest Dermatol 1995; 104: 183-8.
31. 31 Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42.
32. 32 Fisher GJ, Duell EA, Nickoloff BJ et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988; 91: 142-6.
33. 33 Wov YH, Sander DN, McKenzie RC. Cyclosporin A inhibits keratinocyle cytokine gene expression. Br J Dermatol 1994; 130: 312-9.